Company Overview: Onconova

Industry News

21 Mar

Onconova Therapeutics, Inc. to Present at Two Upcoming Healthcare Conferences

NEWTOWN, Pa., March 21, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Company management will present an overview at the Sachs Fifth Annual Cancer Bio Partnering and Investment Forum,...

Read more

2 Mar

Onconova Therapeutics, Inc. to Present at Two Healthcare Conferences in March

NEWTOWN, Pa., March 02, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Company management will present an overview at: Maxim Inaugural Healthcare Investor and Partnering Conference in China 29th...

Read more

27 Jan

Onconova Therapeutics, Inc. to Present at NobleCON13

NEWTOWN, Pa., Jan. 27, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Mark Guerin, Chief Financial Officer, will present a company overview at NobleCON13, Noble Capital Markets’ 13th annual...

Read more

10 Jan

Onconova Therapeutics, Inc. Discusses Target Indications and Clinical Development in New SNNLive Video Interview on StockNewsNow.com

LOS ANGELES, Jan. 10, 2017 /PRNewswire/ — StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Ramesh Kumar, President & CEO of Onconova Therapeutics, Inc. (ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with primary focus on...

Read more

5 Jan

Onconova Therapeutics, Inc. to Present Corporate Overview at Biotech Showcase 2017

NEWTOWN, Pa., Jan. 05, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and Chief Executive Officer, will present a company overview at the Biotech Showcase...

Read more

6 Dec

Onconova and Cellworks Announce Presentation of Rigosertib Predictive Signature for Clinical Response in Myelodysplastic Syndromes (MDS) at 2016 ASH Annual Meeting

NEWTOWN, Pa. and SAN JOSE, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer and Cellworks, a customized therapy design company that improves clinical outcomes and creates value for pharma, payers and...

Read more

5 Dec

Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual Meeting

NEWTOWN, Pa., Dec. 05, 2016 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data from a Phase 2 clinical trial of oral rigosertib and azacitidine in higher-risk myelodysplastic syndromes (HR-MDS) at...

Read more

Page 1 of 41234

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address